<DOC>
	<DOCNO>NCT01279629</DOCNO>
	<brief_summary>The purpose study : To evaluate efficacy drug study treat chronic plaque psoriasis . - Population : 50 patient select sex , healthy , 18 65 year clinical diagnosis chronic plaque psoriasis PASI &lt; 20 % , accord criterion inclusion exclusion .</brief_summary>
	<brief_title>Open Clinical Study , Comparing Non-inferiority Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Age range : Between 18 65 A patient chronic plaque psoriasis PASI &lt; 20 % Presence bilateral lesion least 2 cm diameter degree symmetry Levels serum calcium phosphorus within normal range reference case change , classify irrelevant investigator In case female patient , agreement maintenance safe use contraception barrier ( condom , diaphragm ) , hormonal contraceptive ( pill , implant injection ) , IUDs , abstinence ( sex ) Reading , understanding , agreement signature patient Term Consent . Gestation ( confirm urine test indicator ) Lactation History hypersensitivity component medicine Psoriasis different clinical presentation plat Clinical picture psoriasis involve scalp , face , groin , armpit / intertriginous area Patient require use concomitant medication ( topical systemic ) may alter course disease study period Use systemic treatment psoriasis within 12 week start study Use systemic corticosteroid within 28 day start study Use topical corticosteroid topical therapy area assessment within 02 week start study Use phototherapy ( UVB / UVAP ) within 04 week start study Patients participate another clinical study within 30 day start study Use medication possession disease , opinion investigator might interfere performance interpretation study Laboratory test change ( serum AST ALT , alkaline phosphatase , urea creatinine , total bilirubin fraction ) Patients demonstrate hypercalcemia evidence toxicity vitamin D Other condition deem reasonable medical investigator disqualification individual study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>chronic plaque psoriasis</keyword>
	<keyword>To evaluate efficacy drug study treat chronic plaque psoriasis</keyword>
</DOC>